The Covid vaccine patent waiver has become the subject of global debate following the announcement on May 5th that the US will push for a “waiver of patent protection” at the WTO. Although sold as a humanitarian measure driven by the need to stop the slaughter in India and other countries, the reality is quite different: it is part of a competitive strategy opposed especially by Germany, which is determined to use Covid to capitalize its biotech sector and become the “pharmacy of the world.”
Tag: intellectual property
The “No profit on the pandemic” campaign is spreading an important message throughout Europe: the intellectual property of pharmaceutical companies is a barrier in the way of halting Covid’s spread. Unfortunately, the reasoning is at the very least incomplete and the means unproductive. But it is worth a discussion.